These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 4891871)
21. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Losen M; Martínez-Martínez P; Phernambucq M; Schuurman J; Parren PW; De Baets MH Ann N Y Acad Sci; 2008; 1132():174-9. PubMed ID: 18567867 [TBL] [Abstract][Full Text] [Related]
22. [Laryngeal manifestations of myasthenia. Apropos of a case affecting the dilator muscles of the glottis]. Debain JJ; Lebrigand H; Freyss G Ann Otolaryngol Chir Cervicofac; 1968 Jun; 85(4):273-8. PubMed ID: 5706067 [No Abstract] [Full Text] [Related]
24. Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice. Berman PW; Heinemann SF J Immunol; 1984 Feb; 132(2):711-7. PubMed ID: 6690616 [TBL] [Abstract][Full Text] [Related]
25. [Severity of myasthenia gravis is related to the degree of neuromuscular blocking effect by isoflurane]. Kadosaki M; Enzan K; Horiguchi T; Komatsu H; Suzuki M Masui; 1993 Jun; 42(6):906-9. PubMed ID: 8320811 [TBL] [Abstract][Full Text] [Related]
26. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome]. Andreis I; Lovnićki TJ; Beara N; Taradi M Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205 [TBL] [Abstract][Full Text] [Related]
27. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Punga AR; Flink R; Askmark H; Stålberg EV Muscle Nerve; 2006 Jul; 34(1):111-5. PubMed ID: 16453324 [TBL] [Abstract][Full Text] [Related]
29. The neuromuscular junction. Part II: myasthenia gravis. Brumback RA Am Fam Physician; 1981 Feb; 23(2):126-33. PubMed ID: 7457320 [TBL] [Abstract][Full Text] [Related]
30. Pathogenesis of myasthenia gravis. Br Med J; 1971 Apr; 2(5752):1-2. PubMed ID: 5550865 [No Abstract] [Full Text] [Related]
31. Effects of glucocorticoids on acetylcholine release at the neuromuscular junction [proceedings]. Van Wilgenburg H Br J Pharmacol; 1980 Jan; 68(1):144P. PubMed ID: 7357158 [No Abstract] [Full Text] [Related]
34. Acetylcholinesterase inhibitors in MG: to be or not to be? Punga AR; Stålberg E Muscle Nerve; 2009 Jun; 39(6):724-8. PubMed ID: 19260048 [TBL] [Abstract][Full Text] [Related]
35. Congenital myasthenia: end-plate acetylcholine receptors and electrophysiology in five cases. Vincent A; Cull-Candy SG; Newsom-Davis J; Trautmann A; Molenaar PC; Polak RL Muscle Nerve; 1981; 4(4):306-18. PubMed ID: 7254233 [TBL] [Abstract][Full Text] [Related]
36. Pharmacology of myasthenia gravis. Dipalma JR Am Fam Physician; 1980 Oct; 22(4):158-9. PubMed ID: 7424763 [No Abstract] [Full Text] [Related]
38. The neuromuscular junction with special reference to myasthenia gravis. Hubbard JI Proc Aust Assoc Neurol; 1965; 3():55-60. PubMed ID: 5881782 [No Abstract] [Full Text] [Related]
39. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Pestronk A; Drachman DB; Adams RN Muscle Nerve; 1982 Jan; 5(1):79-84. PubMed ID: 6977088 [TBL] [Abstract][Full Text] [Related]